학술논문
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.
Document Type
journal article
Author
Source
Journal of Clinical Oncology; 8/10/2020, Vol. 38 Issue 23, p2658-2666, 10p
Subject
Language
ISSN
0732183X